Palbociclib
- TRADE NAME: Ibrance (Pfizer)
- INDICATIONS: Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (in combination with letrozole)
- CLASS: CDK4/6 inhibitor
- HALF-LIFE: 29 hours
FDA APPROVAL DATE: 02/03/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Bosentan, Carbamazepine, Clarithromycin, Efavirenz, Etravirine, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Modafinil, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Verapamil, Voriconazole
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN
HAIR
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
HEMATOLOGIC
NEUROMUSCULAR/SKELETAL
OCULAR
RESPIRATORY
OTHER
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of palbociclib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/27/2019
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
